31st Annual Scientific Meeting of
International Society of Cardiovascular Pharmacotherapy
275D
12H
17M
3S
PROGRAMME
| Time | Venue 1 | Venue 2 |
|---|---|---|
| 08:30-09:00 | ISCP CV Team Domains: United in Purpose, Person, Practice and Passion | |
| 09:00-09:30 | Oral Abstract Session 1 | Core Symposium 1: Bleed Less, Protect More: Cracking the Asian Paradox Unpacking the Asian Paradox – What can be done about this discordance? The Singapore data shows that there is an ASEAN Paradox too |
| 09:30-10:00 | Tea Break | |
| 10:00-10:30 | Plenary 1- The Future of Cardiovascular Pharmacotherapy Rewriting DAPT: Where Monotherapy Makes Sense |
|
| 10:30-11:30 | Symposium 1: Matching Novel Heart Failure Therapies to Patient Phenotypes Soluble Guanylate Cyclase Stimulators in Heart Failure: Restoring the NO–cGMP Pathway CRISPR in Cardiovascular Medicine: From Risk Factors to Disease Modification Advanced HF Pharmacotherapies: What Comes After Quadruple Therapy? |
Symposium 2: Closing
the gap in lipid management: From guidelines to real-world impact of siRNA
therapy Lipids management in high CV risk patients: How have we progressed over the years Five Years of siRNA in LDL-C Management: From RCT to RWE & what’s next |
| 11:30-12:00 | Core Symposium 2: From Dyspnoea to Distance: IV Iron and Functional Gains in HF Beyond haemoglobin readings: How might we recognise iron deficiency? IV iron therapy pathways for acute and chronic HF patients – USA x SG |
Oral Abstracts Session 2 (Young Investigator Awards) |
| 12:00-13:00 | Lunch & Exhibition | |
| 13:00-14:00 | Symposium 3: Women’s Heart Health: Rethinking Risk, Recognition, and Response From Pregnancy to Midlife: A Case of HFpEF Emerging After Hypertensive Disorders of Pregnancy SCAD Survivorship: A Recurrence-Risk Case That Changed Our Follow-Up Strategy When Symptoms Speak Louder Than Tests: A Case of Vasomotor Angina Diagnosed Without Devices |
Symposium 4: Cardiomyopathies & Gene-Directed Heart Muscle Disease: Treating the myocardium, not the ventricle Transthyretin Amyloid: Tafamidis + acoramidis, where to sequence? Myosin Inhibition in Hypertrophic Cardiomyopathy: From Mavacamten to Next-Generation Agents |
| 14:00-15:00 | Symposium 5: “How Might I” Optimizing Pharmacotherapy Symposium ARNi, ACEi, ARB, MRA use in recurrent hyperkalaemia Anticoagulation in Special Populations Managing Residual Cardiovascular Risk Beyond LDL-C |
Symposium 6: Precision Cardio-Oncology Across the Cancer Treatment Continuum Risk Stratification & Prevention Before Cancer Therapy Immune Checkpoint Toxicity: Myocarditis, Arrhythmias & Heart Failure Survivorship & Re-Challenge: Long-Term Cardiovascular Risk After Therapy |
| 15:00-15:30 | Tea Break | |
| 15:30-16:30 | Symposium 7: Cardio-Geriatrics: Frailty-First Decisions That Change Outcomes Deprescribing vs Optimising: Finding the Right Treatment Intensity for Frail HF Patients The Ageing Heart: Biomarkers, Frailty Scores & Rejuvenation Therapies (Senolytics & Senomorphics) Frailty & Polypharmacy: Optimising the Opportunities |
Symposium 8: Pulmonary Hypertension Right Heart, Right Drugs, Right Time Seeing the Invisible: Early & Accurate PH Diagnosis Modern PH Therapies: Choosing the Right Drug Class for the Right Patient The PH Escalation Algorithm : When & How to Intensify Therapy |
| 16:30-17:30 | Symposium 9: Why Vaccinations Matter in Cardiovascular Disease Care? Life After Discharge: Understanding the Post Hospitalisation Vulnerability Window in Cardiovascular Patients Integrating the Role of Immunisation in Cardiovascular Care |
Symposium 10: The Future of Cardiovascular Care: AI-nomics, Telehealth, and the New Precision Ecosystem From Model to Bedside: Translating SIMFONi-Enabled AI into Cardiovascular Imaging Practice Digital Biomarkers & Therapeutics: Predicting Deterioration and Improving Adherence in Cardiovascular Care Predicting Heart Failure Before It Happens: Tele-HF, NT-proBNP POCT & AI-Driven Preventive Admissions |
| 17:30-18:30 | Welcome Networking Reception | |
| Time | Venue 1 | Venue 2 |
|---|---|---|
| 08:30-09:30 | Symposium 11: Precision Medicine in Cardiology Precision achievements Collaboration - statin & warfarin Singapore's Pharmacogenomics Position Paper & CYP2C19 implementation |
Symposium 12: Resistant Hypertension Mechanisms & Adherence: Why Patients Stay Hypertensive Unmasking True Resistant Hypertension Renovascular & Renal Parenchymal Hypertension: Who to Screen and When to Treat |
| 09:30-10:00 | Neufeld Lecture - Factor XIa anticoagulants: Is there finally a free lunch in this world? | |
| 10:00-10:30 | Tea Break | |
| 10:30-11:00 | PLENARY 2 - From Atherosclerosis to Adiposity: The Cardiologist’s Expanding Battlefield The Cardiometabolic Patient: What Must We Be Prepared For From Individual Risk to Population Impact: Rethinking Cardiometabolic Prevention at Scale |
|
| 11:00-12:00 | Symposium 13: From Risk to Protection Across the CRM Spectrum | Symposium 14: Arrhythmia & Anticoagulation: Stroke-proof AF Modern AF Detection at Scale : a From Opportunistic Screening to Wearables & Virtual-First Pathways The 2025 AF Treatment Dilemma: Rhythm Control for All Holistic, Stroke-Proof AF Management — Anticoagulation, Comorbidity Control & Lifestyle Interventions |
| 12:00-13:00 | Lunch | |
| 13:00-14:00 | Symposium 15: Learning My ABCD (Adiposity-Based Chronic Disease): The Truth That Weighs on My Heart ABCD as a Cardiovascular Disease: What Single, Dual & Triple Agonists Mean for Prevention and Outcomes ABCD Across the Continuum: How Obesity Shapes HFpEF, Atrial Fibrillation, CKD and Cardiometabolic Risk Enhancing Pharmacotherapy with Digital Health Interventions for Obesity Management |
Symposium 16: Acute & Chronic Coronary Syndrome and Secondary Prevention: Personalising Care Across the Continuum INOCA/MINOCA: Getting the Diagnosis Right With Physiology, Perfusion and Provocation Precision PCI: Stents that Heal Faster + Next-Gen Antithrombotics From IL-6 Blockade to Seasonal Boosters: Targeting Residual Inflammatory Risk |
| 14:00-14:30 | Core Symposium 3: Diabetes, Kidneys and the Heart: A Unified Strategy for Risk Reduction Comparing Tirzepatide and GLP1 RAs: SURMOUNTing effectiveness and adverse reactions How might I Use GIP/GLP safely and effectively? |
Core Symposium 4: From Devices to Decisions: The Future of Ambulatory & Home BP Monitoring Scaling Home Blood Pressure Monitoring: Implementation and Outcomes from the NHS The Singapore Community-based Hypertension and Atrial Fibrillation (HAFib) Program |
| 14:30-15:00 | Tea Break | |
| 15:00-16:00 | Symposium 17: Closing the Gap in Cardiovascular Risk: A 360° Approach to Lipid
Management from Specialists to Primary Care Why early intensification matters? Navigating current challenges and approach to lipid management in ASCVD Closing the gap in cardiovascular risk: Managing ASCVD patients across care continuum |
Symposium 18: Precision Population Health Prevention in Community Cardio4Cities@SH Cardio4Cities@NUHCS NHS experience |
| 16:00-17:00 | Pro-Con Debate: DAPT or Ticagrelor monotherapy in 2026 and beyond? Motion: Ultra-short DAPT should be standard |
|
| Time | Venue 1 | Venue 2 |
|---|---|---|
| 08:30-09:30 | Breakfast Sunday Morning with Experts |
|
| 09:30-10:00 | Tea Break | |
| 10:00-11:00 | Rapid Fire Updates: Shaping Cardiology Practice with Pharmacotherapy Hot Topics 2025/26 Oral PCSK9 Inhibitors: The Next Revolution in Lipid Lowering. Findings from the CORALreef Trial Vericiguat Revisited: Where Does sGC Stimulation Fit in Modern Heart Failure Care? Findings from the VICTOR AND VICTORIA trial Beyond Ablation, New Pharmacometabolic Strategies in AF Study: Findings from the TRANSFORM-AF Trial |
Expert Case Discussion: Controversies in HF & AF Optimisation Adverse-Effect–Driven GDMT Withdrawal: When to Stop, When to Push, and How to Rescue Cardiac Cachexia vs Fluid Overload: The Misread Patient Use of DOACs in renal impairment and endstage renal failure |
| 11:00-12:00 | Closing Keynote – The Future of Cardiovascular Therapy: Regenerate, Personalise, Prevent | |
| 12:00-12:30 | Closing Ceremony + Awards | |